Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

This study tests the combination of nimotuzumab (a targeted antibody) with immune checkpoint inhibitors (immunotherapy drugs) for patients with advanced liver cancer (hepatocellular carcinoma) whose disease has progressed after initial treatment. Researchers are looking for new treatment options for this difficult-to-treat cancer. **You may be eligible if...** - You have been confirmed with advanced hepatocellular carcinoma (liver cancer) - Your cancer has progressed despite prior targeted therapy, immunotherapy, or chemotherapy - Your liver function is relatively well preserved (Child-Pugh grade A or early B) - You have at least one measurable tumor - Your cancer is at an advanced stage (BCLC B or C, or CNLC stage III) **You may NOT be eligible if...** - Your liver function is severely impaired - You have no measurable tumors for tracking - You have not yet tried standard first-line treatments Talk to your doctor to see if this trial is right for you.